FDA, through its Drug Shortages Task Force, will work with CMS to revamp reimbursement policies for critical access drugs, especially sterile injectables, to incentivize manufacturers to invest in and modernize their manufacturing processes and spur development of critical access drugs, FDA Commissioner Scott Gottlieb said during a policy summit on Tuesday (July 17). The two agencies, along with the Department of Veterans Affairs (VA) are considering changing the wholesale acquisition cost or average sales price for a subset of drugs...